全文获取类型
收费全文 | 3119篇 |
免费 | 514篇 |
国内免费 | 57篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 204篇 |
妇产科学 | 18篇 |
基础医学 | 465篇 |
口腔科学 | 46篇 |
临床医学 | 127篇 |
内科学 | 551篇 |
皮肤病学 | 187篇 |
神经病学 | 77篇 |
特种医学 | 19篇 |
外科学 | 1294篇 |
综合类 | 136篇 |
预防医学 | 45篇 |
眼科学 | 79篇 |
药学 | 190篇 |
中国医学 | 62篇 |
肿瘤学 | 180篇 |
出版年
2024年 | 2篇 |
2023年 | 58篇 |
2022年 | 22篇 |
2021年 | 145篇 |
2020年 | 171篇 |
2019年 | 150篇 |
2018年 | 143篇 |
2017年 | 164篇 |
2016年 | 168篇 |
2015年 | 145篇 |
2014年 | 150篇 |
2013年 | 300篇 |
2012年 | 112篇 |
2011年 | 151篇 |
2010年 | 114篇 |
2009年 | 133篇 |
2008年 | 113篇 |
2007年 | 142篇 |
2006年 | 159篇 |
2005年 | 137篇 |
2004年 | 109篇 |
2003年 | 120篇 |
2002年 | 87篇 |
2001年 | 86篇 |
2000年 | 56篇 |
1999年 | 49篇 |
1998年 | 41篇 |
1997年 | 42篇 |
1996年 | 47篇 |
1995年 | 45篇 |
1994年 | 46篇 |
1993年 | 26篇 |
1992年 | 38篇 |
1991年 | 35篇 |
1990年 | 33篇 |
1989年 | 23篇 |
1988年 | 14篇 |
1987年 | 12篇 |
1986年 | 19篇 |
1985年 | 16篇 |
1984年 | 13篇 |
1983年 | 15篇 |
1982年 | 11篇 |
1981年 | 5篇 |
1980年 | 4篇 |
1979年 | 6篇 |
1978年 | 3篇 |
1977年 | 3篇 |
1976年 | 5篇 |
1975年 | 2篇 |
排序方式: 共有3690条查询结果,搜索用时 15 毫秒
1.
2.
3.
《Diagnostic Histopathology》2020,26(12):551-555
This article concentrates on specific infections of the distal gastrointestinal (GI) tract, particularly those that are transmitted sexually, by anal intercourse. Syphilis, gonorrhoea and lymphogranuloma venereum (LGV) are age old and well known diseases, but the features may be unfamiliar to GI histopathologists. Every histopathology trainee will have seen Herpes simplex virus (HSV) infection of squamous epithelium (e.g. oesophagus, vulva and anus), but the HSV pseudotumour of the anus/perineum can present a pitfall to those who have not previously encountered this entity. Another, more recently described, entity that has a predilection for the ano-rectal region is Epstein–Barr Virus (EBV) positive mucocutaneous ulcer, and this also presents a diagnostic trap to the unwary. 相似文献
4.
Giosafat Spitaleri Marta Farrero Torres Mario Sabatino 《Expert opinion on pharmacotherapy》2020,21(11):1367-1376
ABSTRACT
Introduction
Cardiac allograft vasculopathy (CAV) is a major limitation to long-term survival after heart transplantation. Its peculiar pathophysiology involves multifactorial pathways including immune-mediated and metabolic risk factors, which are associated with the development of specific pathological lesions. The often diffuse and chronic nature of the disease reduces the effectiveness of revascularization procedures, and pharmacological prevention of the disease is the sole therapeutic approach with some proven efficacy. 相似文献5.
6.
7.
《Human immunology》2015,76(7):480-487
Previous animal studies showed that donor-derived blood cells treated with mitomycin C (MMC) prolong allograft survival when injected into recipients. This model was effective with whole blood, peripheral blood mononuclear cells (PBMC) (monocytes being the active cell subpopulation) or dendritic cells. In view of a potential clinical application, we study now the immunosuppressive properties of human myeloid cells in vitro. Mature dendritic cells (generated from naïve monocytes) or monocytes treated with mitomycin C do not or only weakly inhibit allogeneic T cells in vitro, whereas cells in an early differentiation state between monocytes and DC exert suppressive activity when treated with MMC. In contrast, DC generated from MMC-treated monocytes show the morphology and phenotype of early immature DC (iDC) and suppress T-cell responses. It is known that untreated monocytes injected into a recipient encounter a cytokine milieu which differentiates them to stimulatory DC. In our in vitro experiment MMC-treated monocytes cultured in a DC-maturing milieu transform themselves into suppressive early iDC. This reproduces a process which takes place when administering MMC-monocytes to a recipient. In conclusion, human MMC-DC or MMC-monocytes are not or only weakly suppressive in vitro. When MMC-monocytes are differentiated to DC the resulting cells become suppressive. 相似文献
8.
9.
Renaud Snanoudj Nassim Kamar Elisabeth Cassuto Sophie Caillard Marie Metzger Pierre Merville Antoine Thierry Isabelle Jollet Philippe Grimbert Dany Anglicheau Marc Hazzan Gabriel Choukroun Bruno Hurault De Ligny Bénedicte Janbon Vincent Vuiblet Anne Devys Yann Le Meur Michel Delahousse Jean-Luc Taupin 《Kidney international》2019,95(6):1471-1485
10.
《Vaccine》2020,38(50):8024-8031
Background and aimsChildren with inflammatory bowel disease (IBD) and autoimmune hepatitis (AIH) receiving immunosuppressive treatment are at risk for severe varicella zoster virus (VZV)-induced disease. This study evaluated vaccination of susceptible patients with stable disease and documented immunoreactivity without interruption of their current immunosuppression (IS).MethodsThis prospective multicentre observational study used a prevaccination checklist to select patients with low-intensity and high-intensity IS for VZV vaccination. Tolerability and safety after immunization were assessed by questionnaire. The immune response was measured by the VZV-IgG concentration, relative avidity index (RAI), and specific lymphocyte proliferative response.ResultsA total of 29 VZV vaccinations were performed in 17 seronegative patients aged 3–16 years (IBD n = 15, AIH n = 2). Eight patients received high-intensity immunosuppression, another six low-intensity immunosuppression, and three patients interrupted IS before VZV vaccination.All 29 vaccinations were well tolerated; only minor side effects such as fever and abdominal pain, were reported in two patients. One patient experienced a flare of Crohn’s disease the day after vaccination.The VZV-IgG-concentration increased significantly (p = 0.018) after vaccination, and a specific lymphocyte response towards VZV in vitro was detected in all tested patients which correlated with the RAI (r = 0.489; p = 0.078).ConclusionsVZV vaccination was well tolerated, safe and immunogenic in children receiving ongoing IS due to IBD and AIH. Ensuring immunoreactivity by clinical and laboratory parameters, rather than the type and dosage of IS, is a reasonable approach to decide on live-attenuated virus vaccinations in immunosuppressed children (German clinical trials DRKS00016357). 相似文献